Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Thursday that one of its operating companies, Par Pharmaceutical, Inc, has started shipping colchicine 0.6mg capsules, a generic version of Hikma's MITIGARE.
The product is intended for prophylaxis of gout flares in adults. It is the first generic colchicine capsule approved by the US Food and Drug Administration.
Scott Sims, Endo senior vice president and general manager, Injectable Solutions & Generics, said, 'We are pleased to offer this high-quality, affordable medication. As a reliable supplier of generic products, we take pride in providing choices to appropriate patients.'
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation